October 3, 2016.
An Irish company has just obtained the right to market an artificial pancreas. This device will facilitate the daily life of type 1 diabetics.
An artificial pancreas to calculate the dose of insulin needed
Science has undoubtedly taken a giant leap forward in the care of people with type 1 diabetes. The American Medicines Agency (FDA) has just authorized the marketing of a device called “artificial pancreas”. The MiniMed 670G is nothing other than a small insulin pump which, thanks to a subcutaneous sensor, makes it possible to instantly measure the blood glucose level. A pump then allows the user to self-administer the dose of insulin he needs.
This marketing authorization comes after a conclusive clinical study carried out on 123 patients, adolescents and adults. All of them suffer from type 1 diabetes and are now carriers of this artificial pancreas supposed to make their daily lives easier..
The FDA still asks for a few more weeks of control
” This device can provide patients with type 1 diabetes more freedom, since they no longer have to constantly and manually monitor baseline glucose levels and administer insulin ”, Explained Jeffrey Shuren, one of the scientific directors of the FDA.
During the next few weeks, however, all these patients will be subjected to a very strict control to verify the correct functioning of the device. In fact, this marketing authorization will only be official after these tests, which should make it possible to verify whether the material is not irritating to the skin or if it does not cause hypoglycemia. . The Irish company behind this device is counting on its first official marketing in the United States in 2017.
Read also: Type 1 diabetes and insulin therapy